Summary & Overview
CPT 90375: Rabies Immunoglobulin for Post-Exposure Passive Immunity
CPT code 90375 identifies rabies immunoglobulin (RIg), a human plasma–derived gamma globulin preparation with high titers of rabies antibodies used for passive immunization after category III rabies exposures. Nationally, RIg is a critical component of rabies post-exposure prophylaxis because it provides immediate neutralizing antibodies until active immunity from rabies vaccination develops. Access to and coverage of RIg affect emergency care pathways and public health responses to potential rabies exposures.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for 90375, typical sites of service, and payer coverage considerations. The publication outlines benchmarking metrics relevant to utilization and reimbursement, highlights policy updates that influence coverage and coding practice, and summarizes clinical implications for delivering timely post-exposure prophylaxis. Where input data are incomplete, the report notes that specific details are not available in the input and focuses on nationally relevant guidance and interpretation rather than jurisdictional specifics.
Billing Code Overview
CPT code 90375 describes rabies immunoglobulin (RIg) derived from pooled human plasma with high-titer antibodies to rabies virus. This biologic provides passive immunity and is used for prevention or treatment of category III rabies exposures, supplying immediate antibodies to neutralize virus at the exposure site.
-
Service type: Administration of a human-derived immunoglobulin product for post-exposure prophylaxis
-
Typical site of service: Emergency department, inpatient facility, urgent care center, or outpatient infusion clinic where rabies post-exposure treatment is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 32-year-old unvaccinated adult presents to the emergency department after a category III exposure: a deep transdermal bite to the forearm by a stray dog while traveling in a rabies-endemic area. Wounds are irrigated and cleansed; tetanus status is verified. Because the patient has not previously received rabies vaccine, passive immunization with human rabies immune globulin is indicated and administered as a single infiltrative dose around the wound and any residual volume given intramuscularly. The typical clinical workflow includes wound care, risk assessment for rabies exposure, informed consent, calculation of the immune globulin dose based on body weight, local infiltration of as much as anatomically feasible into and around the wound, and documentation of lot number, dose, route, site, time, and supervising clinician.
Typical site of service is an emergency department, urgent care clinic, or hospital outpatient infusion/ procedural area. The procedure is performed by emergency medicine physicians, infectious disease specialists, or other credentialed clinicians (physicians, physician assistants, or nurse practitioners) trained to administer immunoglobulin and manage post-exposure prophylaxis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed and documented separately from the immunoglobulin administration (e.g., history, exam, decision-making for PEP). |